Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine

Askari Hasan ¹, Akriti G. Jain ², Huda Naim ³, Alvina Munaf ¹, George Everett ⁴

1. Florida Hospital, Orlando, USA 2. Internal Medicine Residency, Florida Hospital, Orlando, USA 3. Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, PAK 4. Internal Medicine, Florida Hospital, Orlando, USA

Corresponding author: Akriti G. Jain, aky_gupta@yahoo.in

Abstract

Hemolytic uremic syndrome (HUS) is the triad of nonimmune (Coombs negative) hemolytic anemia, low platelet count, and renal impairment. HUS has been associated with a variety of gastrointestinal malignancies and chemotherapeutic agents. We present a patient with pancreatic cancer treated with gemcitabine for palliation who developed gemcitabine-induced HUS (GiHUS) which responded to some extent to blood and platelet transfusions. With the increase in the use of gemcitabine therapy for pancreatic and other malignancies, it is essential to accurately and timely diagnose GiHUS to avoid the life-threatening complications.

Categories: Internal Medicine, Nephrology, Oncology

Keywords: pancreas cancer, atypical hemolytic uremic syndrome

Introduction

Hemolytic uremic syndrome (HUS) is the triad of nonimmune (Coombs negative) hemolytic anemia, low platelet count, and renal impairment [1]. The anemia is severe and microangiopathic in nature, with a platelet count less than 60,000/mm³ in most cases [1].

In children, the disease is most commonly triggered by Shiga-like toxin (Stx)-producing *Escherichia coli*. Non-Shiga toxin-associated HUS can be sporadic or familial and has a poor outcome. Up to 50% of cases progress to end-stage renal disease (ESRD) or have irreversible brain damage, and has an overall 25% mortality [2-4].

HUS has been associated with a variety of gastrointestinal malignancies, most commonly metastatic adenocarcinoma from the stomach, colon, rectum, or pancreas. Certain chemotherapeutic agents have been reported to be associated with HUS, including mitomycin, cisplatin, bleomycin, and more recently gemcitabine [5-6].

Case Presentation

A 66-year-old male with a past medical history of hypertension and pancreatic adenocarcinoma presented to our hospital with complaints of nausea, vomiting, and generalized weakness in the arms and legs. The patient was diagnosed with locally advanced, pancreatic cancer, T1 N0 M0 a year prior to presentation. Magnetic resonance cholangiopancreatography (MRCP) revealed a 1.7 cm mass at the head of his pancreas, locally invasive but without the involvement of lymph nodes, superior mesenteric artery, superior mesenteric vein or portal vein. Endoscopic biopsy revealed adenocarcinoma. The patient was a poor surgical candidate due to social issues, alcoholism, residence at a nursing home and was at a high-risk for post-surgical complications. The patient was treated palliatively with nine cycles of gemcitabine and paclitaxel. The initial dose of gemcitabine was 2000 mg. The tumor decreased in size and CA 19-9 level declined from an initial level of 2000 to 26 units/mL. Later the dose of gemcitabine was reduced to 1400 mg (20% reduction) after the sixth cycle due to pancytopenia.

On admission to our hospital, the patient reported abdominal pain that was sharp and located in the right lower quadrant (RLQ). He denied fevers or chills. The patients' vital signs were: temperature 99.3 °F, heart rate of 73 beats per minute, blood pressure 129/60 mmHg, respiratory rate of 17 breaths per minute and oxygen saturation 100% on room air. The physical examination was remarkable for RLQ tenderness. The laboratory data revealed hemoglobin (Hb) 6.5 g/dL, hematocrit (Hct) 19.8, mean corpuscular volume (MCV) 83.2fL/red cell, red cell distribution width (RDW) 19.1 %, white cell count of 9.44 x 10⁹/L, platelets of 54 x 10⁹/L, alanine transaminase (ALT) 133 IU/L, aspartate transaminase (AST) 222 IU/L, alkaline phosphatase (ALP) of 147 IU/L and a total bilirubin of 5 umol/L. BUN was 42 mg/dl, creatinine 2.12 mg/dl (baseline creatinine of 0.8), LDH was 1700 u/l, reticulocyte count was 7.8%. Peripheral smear showed microcytic anemia with frequent schistocytes consistent with a microangiopathic hemolytic process (Figures 1-2). Urinalysis was positive for 1+ blood and 1+ albumin. Computed tomography (CT) scan of the abdomen without contrast showed a stable pancreatic mass and no signs of hydronephrosis (Figure 3). ERCP revealed

Received 07/25/2018
Review began 07/26/2018
Review ended 07/30/2018
Published 08/02/2018

© Copyright 2018

Hasan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Hasan A, Jain A G, Naim H, et al. (August 02, 2018) Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine. Cureus 10(8): e3088. DOI 10.7759/cureus.3088

choledocholithiasis. Choledocholithotomy was performed and subsequently the bilirubin improved. Blood cultures grew *Klebsiella*. He was treated with piperacillin-tazobactam. The patient received intravenous (IV) fluids, blood and platelets when the Hb and platelets declined to Hb of 6.4 g/dl and platelet counts of 8×10^9 . He was treated with methylprednisone 30 mg IV q24 and the platelet count increased to 20×10^9 . His creatinine increased to 12 mg/dl and BUN to 112 mg/dl. ADAMTS13 activity was 34%. A diagnosis of GiHUS was made. The patient was offered plasmapheresis, but he opted for hospice.

FIGURE 1: Peripheral blood film showing numerous schistocytes

FIGURE 2: Schistocytes under magnification

FIGURE 3: Pancreatic head mass with biliary stent in place

Discussion

Gemcitabine is a nucleoside analog structurally related to cytarabine [7] and is indicated for use in multiple malignancies including pancreatic and non-small cell lung cancer, urothelial and ovarian cancers [8]. The incidence of gemcitabine-induced HUS (GiHUS) has been variously reported to be between 0.015% to 4% [9]. The median time between the initiation of chemotherapy and onset of GiHUS was 7.4 months [10].

Clinically it is very difficult to distinguish HUS associated with underlying malignancy from that caused by chemotherapy. There is considerable etiological overlap in biochemical parameters and tumor factors such as tumor necrosis factor- α , interleukin-1, and interleukin-6 as well as von Willebrand factor (vWF) antigen and low molecular weight vWF multimers [11-12]. Cancer-associated HUS usually occurs during widespread metastatic disease or poorly controlled carcinomas, whereas chemotherapy-associated HUS is more common when the patient is in disease remission or has minimal tumor burden [13]. Carreras [14] and Hammar [15] suggest initial testing for serum C3 concentrations; however, normal C3 levels do not necessarily exclude a complement dysfunction. More sensitive assays could be a higher-than-normal C3d/C3 ratio in plasma or the presence of C3 deposits in renal biopsy.

GiHUS should be suspected in a patient with malignancy whenever renal dysfunction occurs without an obvious cause. Laboratory investigations suggestive of microangiopathic hemolysis should be obtained including red cell morphology, LDH, fibrin split products and reticulocyte count. A renal biopsy can confirm the diagnosis by revealing the classic microvascular damages with arterioles and small arteries occluded by eosinophilic hyaline thrombi containing fibrin and platelet aggregates [16].

In patients suspected of GiHUS, immediate cessation of gemcitabine is the initial step [17]. GiHUS has since its recognition has been associated with a poor prognosis. After the introduction of plasma manipulation, the mortality rate has decreased from 50% to 25% [18]. Removal of plasma and its subsequent substitution with albumin and saline has not been shown to lead to an increase in the platelet count which was seen in our patient. In patients with renal insufficiency or heart failure, plasma exchange within 24 hours of presentation should be considered as first-choice therapy [1]. In a few patients with extensive microvascular thrombosis at renal biopsy, refractory hypertension, and signs of hypertensive encephalopathy, conventional therapies including plasma manipulation are not enough to control the disease. Bilateral nephrectomy has been performed with favorable results in some patients [19]. Other treatments, including antiplatelet agents, prostacyclin, heparin or fibrinolytic agents, steroids, and intravenous immunoglobulins, have been attempted, with no consistent benefit [1].

Eculizumab, a terminal complement inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 complement protein and blocks the generation of proinflammatory C5a and C5b-9 [20]. Clinical trials report that eculizumab resulted in increases in the platelet count, with a mean increase

from baseline to 73×109 per liter ($P < 0.001$) by the 26th week. Eculizumab has been associated with continuous, time-dependent increases in the estimated glomerular filtration rate (GFR) and improvement in health-related quality of life.

Conclusions

With the increase in the use of gemcitabine therapy for pancreatic and other malignancies, it is essential to accurately and timely diagnose GiHUS to avoid the life-threatening complications. Our patient underwent palliative treatment with gemcitabine for pancreatic adenocarcinoma. For any patient receiving gemcitabine like our patient, either therapeutic or palliative, clinicians should have a low threshold for suspecting HUS in the presence of appropriate clinical conditions and laboratory findings especially renal dysfunction.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Ruggenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. *Kidney Int.* 2001, 60:831-846. [10.1046/j.1523-1755.2001.060003831.x](#)
- Gianviti A, Rosmini F, Caprioli A, et al.: Haemolytic-uraemic syndrome in childhood: surveillance and case-control studies in Italy. *Pediatr Nephrol.* 1994, 8:705-709.
- Schieppati A, Ruggenti P, Cornejo RP, et al.: Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. *J Am Soc Nephrol.* 1992, 2:1640-1644.
- Taylor CM, Chua C, Howie AJ, Risdon RA: Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. *Pediatr Nephrol.* 2004, 19:419-425. [10.1007/s00467-003-1385-9](#)
- Cantrell JE, Phillips TM, Schein PS: Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. *J Clin Oncol.* 1985, 5:723-734. [10.1200/JCO.1985.3.5.723](#)
- Montes A, Powles TJ, O'Brien ME, Ashley SE, Luckit J, Treleaven J: A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. *Eur J Cancer.* 1993, 29:1854-1857. [10.1016/0959-8049\(93\)90537-P](#)
- Hui YF, Reitz J: Gemcitabine a cytidine analogue active against solid tumors. *Am J Health Syst Pharm.* 1997, 54:2162-170.
- Brodowicz T, Breiteneder S, Wiltshcke C, Zielinski CC: Gemcitabine-induced hemolytic uremic syndrome: a case report. *J Natl Cancer Inst.* 1997, 89:1895-1896.
- Izzedine H, Isnard-Bagnis C, Launay-Vacher V: Gemcitabine-induced thrombotic microangiopathy: a systematic review. *Nephrol Dial Transplant.* 2006, 21:3038-3045. [10.1093/ndt/gfl507](#)
- Walter RB, Joerger M, Pestalozzi BC: Gemcitabine-associated hemolytic-uremic syndrome. *Am J Kidney Dis.* 2002, 40:E16. [10.1053/ajkd.2002.35758](#)
- Hillyer CD, Duncan A, Ledford M, et al.: Chemotherapy-induced hemolytic uremic syndrome: description of a potential animal model. *J Med Primatol.* 1995, 24:68-73. [10.1111/j.1600-0684.1995.tb00148.x](#)
- Monteagudo J, Pereira A, Roig S, Reverter JC, Ordinas A, Castillo R: Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome. *Am J Hematol.* 1990, 33:46-49.
- Gordon LJ, Kwaan HC: Cancer and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Semin Hematol.* 1997, 34:140-147.
- Carreras L, Romero R, Requesens C, et al.: Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype. *JAMA.* 1981, 245:602-604. [10.1001/jama.1981.03310310044021](#)
- Hammar SP, Bloomer HA, McCloskey D: Adult hemolytic uremic syndrome with renal arteriolar deposition of IgM and C3. *Am J Clin Pathol.* 1978, 70:434-439.
- Saif MW, McGee PJ: Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. *JOP.* 2005, 6:369-374.
- Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD: Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. *Clin Nephrol.* 2009, 71:130-139.
- Kwaan HC, Soff GA: Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Semin Hematol.* 1997, 34:159-166.
- Remuzzi G, Galbusera M, Salvadori M, Rizzoni G, Paris S, Ruggenti P: Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. *Kidney Int.* 1996, 49:282-286.
- Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. *Nat Biotechnol.* 2007, 25:1256-1264. [10.1038/nbt1344](#)